Takeda Pharmaceutical Company Limited today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib as maintenance therapy in patients with multiple myeloma who had received ixazomib, lenalidomide and dexamethasone as induction therapy. The data from this trial demonstrate the potential feasibility of single-agent ixazomib maintenance therapy following 12 cycles of ixazomib-lenalidomide-dexamethasone, with deepening responses and an acceptable tolerability profile.
http://ift.tt/1s9EHI0
http://ift.tt/1s9EHI0
No comments:
Post a Comment